Candesartan in Heart Failure—assessment of reduction in mortality and morbidity - CHARM Overall Programme Results

Description:

The goal of the CHARM Overall Programme Results study was to assess the effect of the long-acting angiotensin II type 1 receptor blocker, candesartan cilexetil, in a broad spectrum of patients with symptomatic heart failure (HF).